Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 76Colorectal Neoplasms 28Breast Neoplasms 23Esophageal Neoplasms 20Pancreatic Neoplasms 13Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Rectal Neoplasms 9Ovarian Neoplasms 8Endometrial Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5HER2-positive Gastric Cancer 5Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Adenocarcinoma 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Bile Duct Neoplasms 3Vulvar Neoplasms 2

Interventions

Trastuzumab 1Paclitaxel 1HM781-36B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER-2 Positive Advanced Gastric Cancer × Trastuzumab × Gastrointestinal × Clear all
NCT01746771 2016-03-03

A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer

Hanmi Pharmaceutical Company Limited

Phase 1/2 Completed
44 enrolled
Gastrointestinal

HER-2 Positive Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡